PepGen Withdraws Prior Guidance With Respect To Timeline For Initiating Phase 1 Study Of PGN-EDODM1, While It Awaits Receipt Of An Official Clinical Hold Letter From FDA
Portfolio Pulse from Benzinga Newsdesk
PepGen has withdrawn its prior guidance for initiating a Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the first half of 2023, as it awaits an official clinical hold letter from the FDA.
June 13, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
PepGen's withdrawal of its prior guidance for initiating a Phase 1 study of PGN-EDODM1 may negatively impact its stock price in the short term.
PepGen's decision to withdraw its prior guidance for initiating a Phase 1 study of PGN-EDODM1 is a direct result of the pending clinical hold letter from the FDA. This regulatory hurdle may cause uncertainty among investors and negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100